PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by 
activation of Akt and EGFR

Sos, Martin; Koker, Mirjam; Weir, Barbara; Heynck, Stefanie; Rabinovsky, Rosalia; Zander, Thomas; Seeger, Jens M.; Weiss, Jonathan; Fischer, Florian; Frommolt, Peter; Michel, Kathrin; Peifer, Martin; Mermel, Craig; Girard, Luc; Peyton, Michael; Gazdar, Adi F.; Minna, John D.; Garraway, Levi A.; Kashkar, Hamid; Pao, William; Meyerson, Matthew; Thomas, Roman K.

Local TagsRelease HistoryDetailsSummary

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

Sos, M., Koker, M., Weir, B., Heynck, S., Rabinovsky, R., Zander, T., et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research, 69(8), 3256-3261.

Item is Released

show all hide all

Basic

show hide

Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D892-0 Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D893-E

Genre: Journal Article

Files

show Files

Locators

show

Creators

show

hide

Creators:
Sos, Martin¹, Author
Koker, Mirjam¹, Author
Weir, Barbara², Author
Heynck, Stefanie¹, Author
Rabinovsky, Rosalia², Author
Zander, Thomas³, Author
Seeger, Jens M.², Author
Weiss, Jonathan¹, Author
Fischer, Florian¹, Author
Frommolt, Peter², Author
Michel, Kathrin¹, Author
Peifer, Martin¹, Author
Mermel, Craig², Author
Girard, Luc², Author
Peyton, Michael², Author
Gazdar, Adi F.², Author
Minna, John D.², Author
Garraway, Levi A.², Author
Kashkar, Hamid², Author
Pao, William², Author
Meyerson, Matthew², AuthorThomas, Roman K.¹, Author          more..

Affiliations:
1Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656
21. Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA 2. Univ Texas SW Med Ctr Dallas, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA 3. Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA 4. Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA 5. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA 6. Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA, ou_persistent22
3Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663

Content

show

Details

show

hide

Language(s): eng - English

Dates: Date issued: 2009-04

Publication Status: Issued

Pages: -

Publishing info: -

Table of Contents: -

Rev. Type: Peer

Identifiers: eDoc: 418492
ISI: 000265314900004

Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show

hide

Title: Cancer Research

Source Genre: Journal

Creator(s):

Affiliations:

Publ. Info: -

Pages: - Volume / Issue: 69 (8) Sequence Number: - Start / End Page: 3256 - 3261 Identifier: ISSN: 0008-5472